Vanguard Group
CBIO

Vanguard Group’s Crescent Biopharma CBIO Stock Holding History

Vanguard Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.61M Sell
557,506
-100,394
-15% -$1.28M ﹤0.01% 3155
2025
Q3 		$7.82M Buy
+657,900
New +$8.73M ﹤0.01% 3107
2025
Q2 		– Sell
-26,702
Closed -$561K – 4296
2025
Q1 		$561K Hold
26,702
– – ﹤0.01% 3858
2024
Q4 		$665K Hold
26,702
– – ﹤0.01% 3868
2024
Q3 		$451K Sell
26,702
-267
-1% -$5.6K ﹤0.01% 3999
2024
Q2 		$759K Sell
26,969
-651
-2% -$67.7K ﹤0.01% 3883
2024
Q1 		$8.29M Buy
27,620
+3,401
+14% +$1.02M ﹤0.01% 3064
2023
Q4 		$5.72M Hold
24,219
– – ﹤0.01% 3227
2023
Q3 		$3.63M Buy
24,219
+1,075
+5% +$170K ﹤0.01% 3379
2023
Q2 		$4.03M Sell
23,144
-1,464
-6% -$245K ﹤0.01% 3409
2023
Q1 		$3.1M Buy
24,608
+1,851
+8% +$417K ﹤0.01% 3513
2022
Q4 		$6.9M Buy
22,757
+3,963
+21% +$584K ﹤0.01% 3140
2022
Q3 		$1.04M Buy
18,794
+326
+2% +$23.4K ﹤0.01% 3987
2022
Q2 		$1.1M Buy
18,468
+318
+2% +$23.5K ﹤0.01% 4056
2022
Q1 		$2.07M Sell
18,150
-4,236
-19% -$497K ﹤0.01% 3945
2021
Q4 		$3.22M Sell
22,386
-214
-0.9% -$38.8K ﹤0.01% 3845
2021
Q3 		$4.95M Sell
22,600
-105
-0.5% -$22.2K ﹤0.01% 3668
2021
Q2 		$5.27M Sell
22,705
-3,876
-15% -$986K ﹤0.01% 3574
2021
Q1 		$8M Buy
26,581
+889
+3% +$318K ﹤0.01% 3277
2020
Q4 		$9.66M Buy
25,692
+8,146
+46% +$2.85M ﹤0.01% 3010
2020
Q3 		$5.39M Buy
17,546
+1,124
+7% +$430K ﹤0.01% 3110
2020
Q2 		$6.17M Sell
16,422
-1,061
-6% -$300K ﹤0.01% 3004
2020
Q1 		$3.99M Buy
17,483
+32
+0.2% +$12.2K ﹤0.01% 3064
2019
Q4 		$9.23M Sell
17,451
-58
-0.3% -$31.4K ﹤0.01% 2898
2019
Q3 		$7.55M Buy
17,509
+115
+0.7% +$74K ﹤0.01% 2971
2019
Q2 		$20.7M Sell
17,394
-964
-5% -$1.15M ﹤0.01% 2495
2019
Q1 		$22.9M Buy
18,358
+98
+0.5% +$112K ﹤0.01% 2442
2018
Q4 		$17.3M Buy
18,260
+1,344
+8% +$1.62M ﹤0.01% 2511
2018
Q3 		$24.4M Buy
16,916
+270
+2% +$408K ﹤0.01% 2490
2018
Q2 		$26.9M Buy
16,646
+1,469
+10% +$2.53M ﹤0.01% 2432
2018
Q1 		$24.6M Buy
15,177
+4,849
+47% +$10.1M ﹤0.01% 2418
2017
Q4 		$17.3M Buy
10,328
+1,096
+12% +$1.45M ﹤0.01% 2542
2017
Q3 		$12.9M Buy
9,232
+790
+9% +$927K ﹤0.01% 2695
2017
Q2 		$9.42M Buy
8,442
+4,097
+94% +$3.38M ﹤0.01% 2807
2017
Q1 		$2.36M Buy
4,345
+101
+2% +$62K ﹤0.01% 3332
2016
Q4 		$2.59M Buy
4,244
+150
+4% +$93.6K ﹤0.01% 3274
2016
Q3 		$2.93M Buy
4,094
+165
+4% +$126K ﹤0.01% 3243
2016
Q2 		$2.86M Buy
3,929
+1,583
+67% +$1.09M ﹤0.01% 3233
2016
Q1 		$1.4M Buy
2,346
+176
+8% +$90.2K ﹤0.01% 3494
2015
Q4 		$1.24M Buy
2,170
+85
+4% +$56.3K ﹤0.01% 3552
2015
Q3 		$1.17M Hold
2,085
– – ﹤0.01% 3582
2015
Q2 		$1.66M Buy
2,085
+6
+0.3% +$4.96K ﹤0.01% 3487
2015
Q1 		$1.73M Buy
2,079
+33
+2% +$25.6K ﹤0.01% 3464
2014
Q4 		$1.47M Buy
2,046
+14
+0.7% +$11K ﹤0.01% 3387
2014
Q3 		$1.41M Buy
2,032
+559
+38% +$452K ﹤0.01% 3402
2014
Q2 		$1.24M Buy
1,473
+215
+17% +$214K ﹤0.01% 3434
2014
Q1 		$2.05M Buy
+1,258
New +$1.52M ﹤0.01% 3209

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return